Tag: Primary Hyperoxaluria

June 20, 2019 Off

Globally Recognized Nephrologist Joins Dicerna™ to Support Continued Development of DCR-PHXC for the Treatment of Primary Hyperoxaluria

– Prof. Bernd Hoppe, M.D., Appointed Vice President, Global Medical Affairs at Dicerna – CAMBRIDGE, Mass.–(BUSINESS WIRE)–Dicerna™ Pharmaceuticals, Inc. (Nasdaq:…

April 15, 2019 Off

Alnylam Initiates ILLUMINATE-B Phase 3 Pediatric Study of Lumasiran for the Treatment of Primary Hyperoxaluria Type 1 and Presents New Positive Results from Phase 2 Open-Label Extension Study

By BusinessWire

The primary endpoint is the percent reduction in urinary oxalate frombaseline to six months. The Company expects to report initialILLUMINATE-B results in mid-2020.